HC Wainwright Increases Earnings Estimates for AC Immune

Key Points

• HC Wainwright raised its FY2026 EPS estimate for AC Immune to ($0.84) from ($0.87) and provided bullish longer‑term projections of $1.11 for FY2028 and $1.56 for FY2029, though the FY2026 estimate remains below the consensus of ($0.69).
• Analyst sentiment is mixed—two Buys, one Hold and one Sell—giving AC Immune an average rating of Hold and a consensus price target of $7.50.
• AC Immune reported Q1 EPS of ($0.19) and revenue of $1.40M, both beat expectations, but the company remains deeply unprofitable with negative margins and a market cap of about $306 million as the stock trades near $3.00.

AC Immune (NASDAQ:ACIU - Free Report) - Stock analysts at HC Wainwright increased their FY2026 earnings estimates for AC Immune in a research note issued to investors on Monday, May 4th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.84) per share for the year, up from their prior estimate of ($0.87). The consensus estimate for AC Immune's current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for AC Immune's FY2028 earnings at $1.11 EPS and FY2029 earnings at $1.56 EPS.

A number of other equities analysts have also recently issued reports on ACIU. Weiss Ratings restated a "sell (d-)" rating on shares of AC Immune in a research report on Monday, April 20th. Jefferies Financial Group restated a "buy" rating and set a $7.00 target price on shares of AC Immune in a research report on Friday, March 13th. BTIG Research restated a "buy" rating and set a $8.00 target price on shares of AC Immune in a research report on Monday. Finally, Wall Street Zen upgraded shares of AC Immune from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $7.50.

AC Immune Stock Performance

Shares of ACIU opened at $3.01 on Wednesday. The company has a current ratio of 0.87, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. The stock has a market cap of $306.33 million, a P/E ratio of -3.67 and a beta of 1.65. The company has a 50-day moving average of $2.94 and a two-hundred day moving average of $3.09. AC Immune has a 12-month low of $1.51 and a 12-month high of $4.00.

AC Immune (NASDAQ:ACIU - Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. The company had revenue of $1.40 million during the quarter, compared to analysts' expectations of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 125.26%.

Hedge Funds Weigh In On AC Immune

Institutional investors have recently modified their holdings of the company. EFG International AG acquired a new position in shares of AC Immune in the fourth quarter valued at approximately $41,000. Private Advisor Group LLC acquired a new position in shares of AC Immune in the third quarter valued at approximately $48,000. Goldman Sachs Group Inc. raised its position in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company's stock valued at $58,000 after buying an additional 5,920 shares during the last quarter. Susquehanna International Group LLP acquired a new position in shares of AC Immune in the third quarter valued at approximately $63,000. Finally, Sei Investments Co. acquired a new position in shares of AC Immune in the second quarter valued at approximately $51,000. Institutional investors and hedge funds own 51.36% of the company's stock.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.